Hanada M, Kishimoto Y, Nakai K, Shimizu T, Matsumoto N, Miyazaki Y, Yamamoto Y, Amakawa R, Fujimoto M, Fukuhara S
First Department of Internal Medicine, Kansai Medical University.
Rinsho Ketsueki. 2000 Jul;41(7):563-7.
We report the response to, and toxicity of antithymocyte globulin (ATG) treatment in 11 consecutive patients (7 men and 4 women; median age 46 years) with aplastic anemia (AA). Six of the patients had severe disease and 5 had moderate disease; all were treated within one year from diagnosis. The ATG regimen was the initial treatment for 6 patients, but a sequential treatment for the other 5. Cyclosporin A was administered orally 1-3 weeks after the ATG treatment. All patients were assessed for over 6 months (median, 20.4 months); 8 showed a good response, 1 a minimal response, and 2 no response. Disease severity had no influence on the response. In 1 patient, ATG treatment had to be discontinued because of hepatic toxicity. However, adverse reactions were not severe in the other 10 patients. These findings suggest that ATG treatment is a safe and effective therapy for AA.
我们报告了连续11例再生障碍性贫血（AA）患者（7例男性，4例女性；中位年龄46岁）接受抗胸腺细胞球蛋白（ATG）治疗的反应及毒性。其中6例患者病情严重，5例病情中等；所有患者均在诊断后1年内接受治疗。ATG方案对6例患者为初始治疗，但对另外5例为序贯治疗。ATG治疗1 - 3周后口服环孢素A。所有患者均接受了超过6个月（中位时间20.4个月）的评估；8例反应良好，1例反应轻微，2例无反应。疾病严重程度对反应无影响。1例患者因肝毒性不得不停止ATG治疗。然而，其他10例患者的不良反应并不严重。这些发现表明，ATG治疗是一种安全有效的AA治疗方法。
